1294P RELAY, erlotinib plus ramucirumab or placebo in untreated EGFR-mutated metastatic NSCLC: Outcomes by EGFR mutation type
Nakagawa, K., Nadal, E., Garon, E.B., Nishio, M., Seto, T., Yamamoto, N., Park, K., Shih, J-Y., Frimodt-Moller, B., Zimmermann, A.H., Visseren-Grul, C.M., Reck, M.
Published in Annals of oncology (01.09.2020)
Published in Annals of oncology (01.09.2020)
Get full text
Journal Article
Patient-focused outcomes in RELAY, a phase III trial of ramucirumab plus erlotinib (RamErl) versus placebo plus ERL (PboErl) in untreated EGFR-mutated metastatic NSCLC (EGFR+ mNSCLC)
Yoh, K., Atagi, S., Reck, M., Garon, E.B., Aix, S. Ponce, Moro-Sibilot, D., Winfree, K.B., Frimodt-Moller, B., Zimmermann, A.H., Visseren-Grul, C.M., Nakagawa, K.
Published in Annals of oncology (01.11.2019)
Published in Annals of oncology (01.11.2019)
Get full text
Journal Article
P1.18-01 RELAY EU/US Subset: Ramucirumab Plus Erlotinib Improves Progression-Free Survival in First-Line EGFR Mutation-Positive NSCLC
Aix, S., Novello, S., Garon, E., Nakagawa, K., Nadal, E., Moro-Sibilot, D., Garcia, M. Alonso, Fabre, E., Frimodt-Moller, B., Zimmermann, A., Visseren-Grul, C., Reck, M.
Published in Journal of thoracic oncology (01.10.2019)
Published in Journal of thoracic oncology (01.10.2019)
Get full text
Journal Article
35P Final data from phase I/II LIBRETTO-001 trial of selpercatinib in RET fusion-positive non-small cell lung cancer
Gautschi, O., Drilon, A., Solomon, B., Tomasini, P., Loong, H.H.F., De Braud, F.G.M., Goto, K., Peterson, P., Barker, S., Liming, K., Frimodt-Moller, B., Park, K.
Published in ESMO open (01.03.2024)
Published in ESMO open (01.03.2024)
Get full text
Journal Article
Phase 1b expansion cohort study to evaluate the safety and efficacy of necitumumab and abemaciclib combination therapy in patients with stage IV non-small cell lung cancer (NSCLC)
Besse, B., Barlesi, F., Ceccarelli, M., Chao, G.Y., Frimodt-Moller, B., Gil, M., Vansteenkiste, J.
Published in Annals of oncology (01.10.2016)
Published in Annals of oncology (01.10.2016)
Get full text
Journal Article
135O A phase 1b study of necitumumab in combination with abemaciclib in patients with stage IV non-small cell lung cancer
Besse, B., Barlesi, F., Demedts, I., Fuentes Pradera, J., Renault, A., Robinet, G., Frimodt-Moller, B., Gil, M., Vansteenkiste, J.
Published in Journal of thoracic oncology (01.04.2018)
Published in Journal of thoracic oncology (01.04.2018)
Get full text
Journal Article
A phase 1b study of necitumumab in combination with abemaciclib in patients with stage IV non-small cell lung cancer: 135O
Besse, B, Barlesi, F, Demedts, I, Pradera, Fuentes J, Renault, A, Robinet, G, Frimodt-Moller, B, Gil, M, Vansteenkiste, J
Published in Journal of thoracic oncology (01.04.2018)
Published in Journal of thoracic oncology (01.04.2018)
Get full text
Journal Article
Quality-of-life (QoL) measures in advanced non-small cell lung cancer (NSCLC) patients and their association with treatment choices across 5 European countries: Preliminary data from the ACTION study
Pimental, F., Szczepura, A., Thomas, M., Frimodt-Moller, B., Belger, M., Watkins, J., Watt, M.
Published in Journal of clinical oncology (01.06.2005)
Published in Journal of clinical oncology (01.06.2005)
Get full text
Journal Article
P-458 Palliative chemotherapy of non-small cell lung cancer (NSCLC): Analysis of German baseline data from the ACTION observational study
Bischoff, H., Leschinger, M., Bhalla, S., Mueller, E., Frimodt-Moller, B., Bonnet, R., Steppert, O., Fischer, J., Boulori, H., Thomas, M.
Published in Lung cancer (Amsterdam, Netherlands) (01.07.2005)
Published in Lung cancer (Amsterdam, Netherlands) (01.07.2005)
Get full text
Journal Article